UA123537C2 - Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів - Google Patents

Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів Download PDF

Info

Publication number
UA123537C2
UA123537C2 UAA201704069A UAA201704069A UA123537C2 UA 123537 C2 UA123537 C2 UA 123537C2 UA A201704069 A UAA201704069 A UA A201704069A UA A201704069 A UAA201704069 A UA A201704069A UA 123537 C2 UA123537 C2 UA 123537C2
Authority
UA
Ukraine
Prior art keywords
compound
liver disease
receptor
liver
fatty liver
Prior art date
Application number
UAA201704069A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джозеф К. БЕЛАНОФФ
Хейзл Хант
Хэйзл Хант
Онно С. Меєр
Онно С. Меер
ден Хьовел Йосе ван
Original Assignee
Корцепт Терап'Ютікс, Інк.
Корцепт Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Корцепт Терап'Ютікс, Інк., Корцепт Терапьютикс, Инк. filed Critical Корцепт Терап'Ютікс, Інк.
Publication of UA123537C2 publication Critical patent/UA123537C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201704069A 2014-10-15 2015-10-14 Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів UA123537C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
UA123537C2 true UA123537C2 (uk) 2021-04-21

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201704069A UA123537C2 (uk) 2014-10-15 2015-10-14 Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (2) EP3206692B1 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN107106562B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (1) DK3206692T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (1) FI3206692T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (1) PT3206692T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
SG11202011948SA (en) * 2018-06-04 2020-12-30 Corcept Therapeutics Inc Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
JP2023524780A (ja) * 2020-05-06 2023-06-13 コーセプト セラピューティクス, インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイド受容体モジュレーターの多形
US12144812B2 (en) * 2020-05-06 2024-11-19 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
US11827608B2 (en) 2020-12-21 2023-11-28 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
AU2022271209A1 (en) * 2021-05-05 2023-11-09 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
DE602006013448D1 (de) 2005-05-18 2010-05-20 Merck Sharp & Dohme D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
CN101313066A (zh) 2005-09-19 2008-11-26 强生医药研究及开发有限责任公司 糖皮质激素受体表达的调节
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CA2683915A1 (en) 2007-04-13 2008-10-23 Schering Corporation Pyrimidinedione derivatives and methods of use thereof
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
BRPI1008709B8 (pt) 2009-04-03 2021-05-25 Hoffmann La Roche dispersão sólida, formulação, composição e comprimido compreendendo {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridina-3-carbonil]-2,4-diflúor-fenil}-amida do ácido propano-1-sulfônico
SG193509A1 (en) * 2011-03-18 2013-10-30 Corcept Therapeutics Inc Pyrimidine cyclohexyl glucocorticoid receptor modulators
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
JP6761410B2 (ja) 2020-09-23
EP4353310A3 (en) 2024-06-19
EP3206692B1 (en) 2024-04-03
CN107106562A (zh) 2017-08-29
KR20170066646A (ko) 2017-06-14
RU2718921C2 (ru) 2020-04-15
FI3206692T3 (fi) 2024-05-06
PH12017500710A1 (en) 2017-10-09
PL3206692T3 (pl) 2024-07-22
ES2978871T3 (es) 2024-09-23
US12226417B2 (en) 2025-02-18
EP4353310A2 (en) 2024-04-17
RU2017114596A3 (enExample) 2019-05-08
IL251729A0 (en) 2017-06-29
WO2016061195A1 (en) 2016-04-21
KR102435956B1 (ko) 2022-08-23
AU2015333645B2 (en) 2020-01-30
BR112017007860B1 (pt) 2023-03-07
CA2964625A1 (en) 2016-04-21
PH12017500710B1 (en) 2024-01-17
DK3206692T3 (da) 2024-04-29
US20160106749A1 (en) 2016-04-21
NZ731060A (en) 2023-07-28
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
EP3206692A1 (en) 2017-08-23
US20230218621A1 (en) 2023-07-13
MX2017004943A (es) 2017-07-19
ZA201702813B (en) 2019-05-29
US20190151318A1 (en) 2019-05-23
PT3206692T (pt) 2024-04-30
CN111557942B (zh) 2023-10-03
CA2964625C (en) 2023-03-07
EP3206692A4 (en) 2018-05-30
US20210085682A1 (en) 2021-03-25
BR112017007860A2 (pt) 2018-01-16
CN111557942A (zh) 2020-08-21
AU2015333645A1 (en) 2017-05-04
SG11201703024VA (en) 2017-05-30
RU2017114596A (ru) 2018-11-15
US10238659B2 (en) 2019-03-26
CN107106562B (zh) 2020-08-18
IL251729B (en) 2020-03-31
JP2017531013A (ja) 2017-10-19
US11590135B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
UA123537C2 (uk) Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів
US12263169B2 (en) Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
UA127409C2 (uk) Модулятори глюкокортикоїдного рецептора для лікування раку шийки матки
KR20190040511A (ko) 췌장암을 치료하기 위한 글루코코르티코이드 수용체 조정제
Adam et al. Sympathoexcitation in response to cardiac and pulmonary afferent stimulation of TRPA1 channels is attenuated in rats with chronic heart failure
CA2619480A1 (en) Method of using potassium channel inhibiting compounds
Zhao et al. JTC-801 inhibits the proliferation and metastasis of the Hep G2 hepatoblastoma cell line by regulating the phosphatidylinositol 3-kinase/protein kinase B signalling pathway
HK40102771A (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087B (zh) 使用糖皮質激素和鹽皮質激素受體拮抗劑的脂肪肝疾病治療
CN120265281A (zh) 用于治疗肌肉病症的爱帕琳肽受体激动剂
HK40027249A (en) Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators
HK40027249B (en) Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators